There were some posts recently re the possible role of the glutaminase switch in leading to castration resistance. The following trial - A Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With the PARP Inhibitor Talazoparib in Participants With Metastatic Castration-Resistant Prostate Cancer is opening in July to test this option
Although it includes a PARP inhibitor, this trial is looking at only men who test negative for BRCA.
Very interesting post and thank you Nal for the reply. Glutamine seems to be an important factor in CRPC disease. I might be looking on Amazon for Ashwagandha, LOL
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.